Recently, the MTTP inhibitor lomita-pide has been registered on the European and US markets for the treatment of unresponsive homozygous familial hypercholesterolemia, despite some limitations regarding its side effects [44]. This evidence concerns the gene MT-TP and familial hypercholesterolemia.